Optimizing Lead 5-HT2c Ligands for Use in the Treatment of Schizophrenia
优化用于治疗精神分裂症的 5-HT2c 铅配体
基本信息
- 批准号:8469720
- 负责人:
- 金额:$ 79.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-07-05 至 2017-05-31
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAffectAffinityAgonistAmygdaloid structureAnimal ModelAnimal TestingAnimalsAntipsychotic AgentsAreaBehaviorBehavior assessmentBehavioralBehavioral AssayBehavioral ModelBindingBiological AssayBipolar DisorderBoxingCell Culture TechniquesCell NucleusCharacteristicsChemicalsClinicClinicalClinical TrialsCognitionCognitiveComputer SimulationContractsDelusionsDeteriorationDevelopmentDiseaseDopamineDrug DesignDrug abuseEvaluationFailureGenderGeneticGenetic ModelsGoalsHTR2A geneHallucinationsHippocampus (Brain)HousingHumanHygieneHypertrophyHypothalamic structureImpaired cognitionIn VitroIncidenceIntuitionKnockout MiceLeadLifeLigandsMedicalMental DepressionMental disordersMetabolicMolecular TargetMusNational Institute of Mental HealthNeurobehavioral ManifestationsNucleus AccumbensObesityObsessive-Compulsive DisorderOutcomePharmaceutical ChemistryPharmaceutical PreparationsPharmacologic SubstancePopulationPre-Clinical ModelPreclinical Drug EvaluationProcessProsencephalonProtein IsoformsPsychotic DisordersPsychotropic DrugsRaceRefractoryResearchSchizophreniaSchoolsSerotoninSerotonin AgonistsSerotonin Receptor 5-HT2BSerotonin Receptor 5-HT2CSolubilitySpecificityStagingStructure of choroid plexusSymptomsTardive DyskinesiaTestingThinkingVentral Tegmental AreaVesicular stomatitis Indiana virusWithdrawalWorkaddictionatypical antipsychoticbasedesigndrug candidateimprovedin vivoinnovationinterestmRNA Expressionmouse modelneuropsychiatrynigrostriatal systemnovelnovel therapeuticspre-clinicalprogramspublic health relevanceradioligandreceptorresearch studysocialtooltreatment strategy
项目摘要
DESCRIPTION (provided by applicant): Our ultimate goal is to synthesize and characterize novel 5-HT2c serotonin agonists that may be useful for treating schizophrenia and related disorders. Our preliminary findings, as well as those of others, indicate that 5-HT2C agonists are effective in animal models predictive of efficacy against the positive and cognitive symptoms of schizophrenia. Because 5-HT2C agonists are not associated with the metabolic and motoric side- effects characteristic of current typical and atypical antipsychotic drugs, 5-HT2C agonists would afford novel treatment strategies for schizophrenia and related disorders. To achieve this overall goal we have three specific aims. Aim 1: To further expand and improve upon the potent 5-HT2c ligands that we have already identified using rational drug design principles and chemical intuition. Structural alterations will be made to enhance 5-HT2c subtype selectivity and to avoid any 5-HT2B valvuopathic-associated activity, while also improving upon compound solubility and ADMET parameters as needed to achieve the desired efficacy in preclinical animal studies. Aim 2: Characterize binding affinities and functional activities of putative 5-HT2c
agonists for the human and mouse 5-HT2c-INI, 5-HT2c-NVN and 5-HT2c-VSV receptor-isoforms. We will also evaluate specificity of putative 5-HT2c agonists by assessing 5-HT2A and 5-HT2B receptor activities by radioligand binding and functional assays. The best compounds emerging from these studies will be subjected to a large battery of assays for identification of off-target activity. Aim 3: To evaluate the best 5-HT2c ligands identified in Specific Aims 1 and 2
in a battery of schizophrenia- related behavioral assays to test for antipsychotic efficacy and possible pro-cognitive effects. The behavioral studies will be conducted with pharmacological and genetic models of schizophrenia-like behaviors; 5-HT2C- knockout mice will serve as controls. The strength of this proposal lies in: (1) Targeting a receptor for which there are no currently approved medications (i.e. a novel molecular target); (2) 5-HT2C agonists are likely to have clinical indications beyond schizophrenia including bipolar disorder, depression, obesity, and drug abuse (i.e. many potential clinical indications); (3) With respect to schizophrenia, two different 5-HT2C agonists have already shown efficacy in animal models predictive of efficacy for positive- and cognitive-like schizophrenia symptoms. Since cognitive symptoms are very difficult to treat in schizophrenia, the 5-HT2C compounds may represent a novel treatment strategy; (4) Finally, it is likely that 5-HT2C agonists will not only be devoid of the metabolic ad motoric side- effects associated with current medications but may also be beneficial from a metabolic perspective.
描述(申请人提供):我们的最终目标是合成和表征可能用于治疗精神分裂症和相关疾病的新型5-HT2C 5-羟色胺激动剂。我们和其他人的初步发现表明,5-HT2C激动剂在动物模型中是有效的,可以预测对精神分裂症的阳性和认知症状的疗效。由于5-HT2C激动剂与当前典型和非典型抗精神病药物所特有的代谢和运动副作用无关,5-HT2C激动剂将为精神分裂症和相关疾病提供新的治疗策略。为了实现这一总体目标,我们有三个具体目标。目的1:利用合理的药物设计原则和化学直觉,进一步扩展和改进我们已经确定的有效的5-HT2C配体。将进行结构改变,以提高5-HT2C亚型的选择性,避免任何与5-HT2B瓣膜病变相关的活性,同时还将根据需要改善化合物的溶解度和适形参数,以在临床前动物研究中达到预期的效果。目的2:表征5-HT2C的结合亲和力和功能活性
人和小鼠5-HT2C-INI,5-HT2C-NVN和5-HT2C-VSV受体-异构体的激动剂。我们还将通过放射配基结合和功能分析评估5-HT2A和5-HT2B受体的活性,以评估可能的5-HT2C激动剂的特异性。从这些研究中发现的最好的化合物将接受大量的测试,以确定脱离目标的活性。目的3:评价特定目标1和2中确定的最佳5-HT2C配体
在一系列与精神分裂症相关的行为分析中,测试抗精神病药物的疗效和可能的促进认知的效果。行为学研究将使用类似精神分裂症行为的药理学和遗传学模型进行;5-HT2C基因敲除小鼠将作为对照。这项建议的力量在于:(1)针对目前尚无药物治疗的受体(即新的分子靶点);(2)5-HT2C激动剂很可能在精神分裂症以外的临床症状中具有疗效,包括双相情感障碍、抑郁、肥胖和药物滥用(即许多潜在的临床适应症);(3)关于精神分裂症,两种不同的5-HT2C激动剂已经在动物模型中显示出疗效,预测对阳性和认知样精神分裂症症状的疗效。由于精神分裂症的认知症状很难治疗,5-HT2C化合物可能代表着一种新的治疗策略;(4)最后,5-HT2C激动剂很可能不仅没有与目前药物相关的代谢和运动副作用,而且从代谢角度来看也可能是有益的。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Bryan L. Roth其他文献
A novel ligand selectively visualizes and activates chemogenetic receptors in non-human primates
一种新型配体选择性地可视化和激活非人类灵长类动物的化学遗传受体
- DOI:
- 发表时间:
2020 - 期刊:
- 影响因子:0
- 作者:
永井裕司;宮川尚久;Xi-Ping Haung;Samuel T. Slocum;Yan Xiong;堀由紀子;小山佳;季斌;平林敏行;藤本淳;三村喬生;Justin G. English;Jing Liu;井上謙一;熊田勝志;関千江;張明栄;須原哲也;高田昌彦;樋口真人;Jian Jin;Bryan L. Roth;南本敬史;Yuji Nagai - 通讯作者:
Yuji Nagai
236 - Regulation of the internalization of the 5HT<sub>2A</sub> receptor in vitro
- DOI:
10.1016/s0920-9964(97)82244-x - 发表时间:
1997-01-01 - 期刊:
- 影响因子:
- 作者:
Sally A. Berry;Laith Alsayegh;Bryan L. Roth - 通讯作者:
Bryan L. Roth
PS I-10
- DOI:
10.1016/s1734-1140(11)70453-4 - 发表时间:
2011-12-30 - 期刊:
- 影响因子:3.800
- 作者:
Jakub Fichna;Kevin Lewellyn;Feng Yan;Bryan L. Roth;Jordan K. Zjawiony - 通讯作者:
Jordan K. Zjawiony
High-dose olanzapine for treatment-resistant schizophrenia.
高剂量奥氮平治疗难治性精神分裂症。
- DOI:
10.4088/jcp.v69n0201 - 发表时间:
2008 - 期刊:
- 影响因子:0
- 作者:
Bryan L. Roth - 通讯作者:
Bryan L. Roth
Structure-Based Discovery of a NPFF1R Antagonist with Analgesic Activity
基于结构的具有镇痛活性的 NPFF1R 拮抗剂的发现
- DOI:
10.1101/2023.10.25.564029 - 发表时间:
2023 - 期刊:
- 影响因子:0
- 作者:
Brian J. Bender;J. E. Pickett;J. Braz;Hye Jin Kang;Stefan Gahbauer;Karnika Bhardwaj;Sian Rodriguez;Yongfeng Liu;Manish K. Jain;Allan I Basbaum;Bryan L. Roth;B. Shoichet - 通讯作者:
B. Shoichet
Bryan L. Roth的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Bryan L. Roth', 18)}}的其他基金
Mechanistic insights into LSD actions at 5-HT2A serotonin receptors
LSD 对 5-HT2A 血清素受体作用的机制见解
- 批准号:
10550420 - 财政年份:2023
- 资助金额:
$ 79.84万 - 项目类别:
STRUCTURE AND FUNCTION OF MRG-FAMILY RECEPTORS
MRG 家族受体的结构和功能
- 批准号:
10419804 - 财政年份:2022
- 资助金额:
$ 79.84万 - 项目类别:
STRUCTURE AND FUNCTION OF MRG-FAMILY RECEPTORS
MRG 家族受体的结构和功能
- 批准号:
10593175 - 财政年份:2022
- 资助金额:
$ 79.84万 - 项目类别:
Mechanistic insights into LSD actions at 5-HT2A serotonin receptors
LSD 对 5-HT2A 血清素受体作用的机制见解
- 批准号:
10356900 - 财政年份:2018
- 资助金额:
$ 79.84万 - 项目类别:
Mechanistic insights into LSD actions at 5-HT2A serotonin receptors
LSD 对 5-HT2A 血清素受体作用的机制见解
- 批准号:
9496860 - 财政年份:2018
- 资助金额:
$ 79.84万 - 项目类别:
Mechanistic insights into LSD actions at 5-HT2A serotonin receptors
LSD 对 5-HT2A 血清素受体作用的机制见解
- 批准号:
10112869 - 财政年份:2018
- 资助金额:
$ 79.84万 - 项目类别:
Molecular Details of Psychoactive Drug Actions
精神活性药物作用的分子细节
- 批准号:
10557802 - 财政年份:2017
- 资助金额:
$ 79.84万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 79.84万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 79.84万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 79.84万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 79.84万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 79.84万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 79.84万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 79.84万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 79.84万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 79.84万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 79.84万 - 项目类别:
Grant-in-Aid for Early-Career Scientists